Ede, Netherlands, 17 April 2019 – Weener Plastics Group today announced the appointment of Erik van den Heuvel as Interim Chief Financial Officer. As of today, Erik van den Heuvel succeeds Tanja Schischka, who decided to leave the company for private family matters after more than three years.

Erik van den Heuvel has 20 years of experience in financial management positions in international Dutch companies. Before joining Weener Plastics, Erik van den Heuvel worked at Accell Group. Among other things, he acted as Interim CFO and was responsible for strategy transition projects. Prior to that, he spent 18 years in senior management positions at Ahold NV, where he was responsible for Business Planning & Performance. Erik van den Heuvel gained extensive experience abroad, working in the United States and Argentina for more than 10 years.

Roel Zeevat, CEO of Weener Plastics, said: "We are very pleased that Erik van den Heuvel is joining Weener Plastics Group as new Interim CFO. Due to his many years of experience in finance departments of international corporates, among others in Latin America and the United States, he knows the business very well and will support us to secure further sustainable growth and to drive our international expansion strategy."

Zeevat continued: "At the same time, we regret Tanja Schischka's decision and we would like to thank her for her outstanding commitment and the contribution she made to the development of the Group. She established the central finance department, improved the compliance and reporting function and was part of the management team that actively pursued the acquisitions of Proenfar, Artpack and Orange Brazil. We wish her the very best and continued success for the future."

Over the past few years, Weener Plastics has made great progress: The company strengthened its geographic footprint and added new innovative products to the existing portfolio. In addition, the company increased its market share in strategic product categories such as deodorant packaging and expanded into new end markets, for example in pharmaceuticals.

17 Apr 2019